The upholding of ProQR's patent in Japan is a significant legal victory that not only secures its intellectual property rights but also potentially enhances its competitive edge in the RNA editing market. This development is likely to be viewed positively by investors, as it solidifies the company's standing in a highly specialized and competitive field, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.